PolyActiva presents positive clinical trial results at the 2022 American Glaucoma Society Annual Meeting – March 2022
PolyActiva successfully completes initial clinical trial with Latanoprost FA SR Ocular Implant delivering glaucoma treatment to patients over a six-month period.
PolyActiva appoints Tracy Valorie, ophthalmic industry expert and former Bausch + Lomb executive, to its Board of Directors.
PolyActiva completes recruitment in key Phase I glaucoma implant safety study. Six-month treatment period demonstrated.